PR Newswire BiotechnologyCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 04:20:00·⟳ 抓取 04:20:19 +19s·⚡ 决策 08-29 04:21:33 +1m14s·59.9 天前
Aardvark Therapeutics股东诉讼招揽公告重复提示既有证券欺诈集体诉讼
本条没有新增公司级基本面或诉讼进展，只是同一AARD证券欺诈诉讼的重复律所广告，已由多家律所提前数日发布，缺乏可交易新增预期差。
📄 原文PR Newswire Biotechnology↗ 原文
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSAL…
不做 Aardvark Therapeutics, Inc.（AARD.US）
不做：本条只是同一证券集体诉讼的重复律所广告，未新增法院进展、监管事实、临床数据或量化损害，做空催化不够新也不够强。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
AARD诉讼指控源自ARD-101此前安全性与FDA临床暂停事件；本次PR Newswire稿件仅提示投资者联系律所和10月13日首席原告期限。搜索显示同一诉讼、同一指控和同一截止日已在8月17日、8月19日、8月24日、8月25日、8月27日多次公开传播，因此不是新的强空催化，也不支持事件驱动交易。
消息传播链
- 较早公开称AARD证券集体诉讼已提交，类别期为2025-02-13至2026-05-14，核心指控为ARD-101安全性和前景披露问题。
- 另一家律所已提示同一10月13日首席原告截止日，并列出2月27日试验暂停和5月14日FDA full clinical hold作为股价下跌节点。
- 同一诉讼再次被律所公告扩散，未见新增法院裁定或公司运营事实。
- 本次信号是同一诉讼的投资者招揽稿，没有新增金额、裁判、监管或临床事实。
主要风险
- 真正影响AARD的负面事实是此前HERO试验暂停和FDA full clinical hold，而不是本条重复律师广告。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-17 · 影响 weakens
搜索命中更早的同一诉讼公告和多家律所重复招揽，削弱本次作为新增做空催化的意义。
检索:AARD securities class action October 13 2026 ARD-101 safety lawsuit earlier announcement 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足未改变结论；核心决策由重复传播和无新增事实决定。
方向:未使用外部事件研究先例；本条在重复消息检查后已经可判定为无新增可交易事实。
涨幅量级:不适用，律师广告未披露新增赔偿、罚款、临床进展或收入影响。
形态:此类多律所集体诉讼招揽公告通常是既有负面事件后的传播尾声，本次也已被多家律所重复发布。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,326 字
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BENSALEM, Pa., Aug. 28, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK THERAPEUTICS, INC. (AARD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE OCTOBER 13, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Is The Lawsuit About?
The complaint filed in this class action alleges that between February 10, 2025 and May 14, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (i) ARD-101 was less safe than Defendants had led investors to believe; (ii) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com
SOURCE Law Offices of Howard G. Smith
BENSALEM, Pa., Aug. 28, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK THERAPEUTICS, INC. (AARD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE OCTOBER 13, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Is The Lawsuit About?
The complaint filed in this class action alleges that between February 10, 2025 and May 14, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (i) ARD-101 was less safe than Defendants had led investors to believe; (ii) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com
SOURCE Law Offices of Howard G. Smith
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。